Oak Harvest Investment Services Sells 7,084 Shares of Amgen Inc. (NASDAQ:AMGN)

Oak Harvest Investment Services reduced its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 26.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,041 shares of the medical research company's stock after selling 7,084 shares during the quarter. Oak Harvest Investment Services' holdings in Amgen were worth $5,223,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of AMGN. State Street Corp raised its position in shares of Amgen by 1.2% in the third quarter. State Street Corp now owns 29,317,018 shares of the medical research company's stock valued at $9,446,236,000 after purchasing an additional 345,537 shares during the period. Geode Capital Management LLC boosted its stake in shares of Amgen by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 12,122,889 shares of the medical research company's stock valued at $3,893,771,000 after purchasing an additional 103,851 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Amgen by 2.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 10,532,629 shares of the medical research company's stock valued at $3,393,718,000 after purchasing an additional 251,876 shares in the last quarter. Janus Henderson Group PLC boosted its position in Amgen by 11.7% during the 3rd quarter. Janus Henderson Group PLC now owns 5,143,330 shares of the medical research company's stock worth $1,657,183,000 after buying an additional 538,545 shares during the period. Finally, Pathway Financial Advisers LLC boosted its position in Amgen by 33,125.4% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,460,181 shares of the medical research company's stock worth $1,437,115,000 after buying an additional 4,446,757 shares during the period. Institutional investors own 76.50% of the company's stock.

Analysts Set New Price Targets

Several research analysts have issued reports on AMGN shares. Barclays raised their price target on shares of Amgen from $300.00 to $315.00 and gave the stock an "equal weight" rating in a report on Monday, October 7th. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Bank of America reiterated an "underperform" rating and set a $256.00 price target on shares of Amgen in a report on Tuesday, December 10th. Piper Sandler cut their price target on Amgen from $344.00 to $310.00 and set an "overweight" rating for the company in a research note on Thursday, January 2nd. Finally, Leerink Partners cut their price target on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Amgen presently has a consensus rating of "Hold" and an average price target of $314.00.

Amgen Stock Performance

NASDAQ AMGN traded up $0.23 on Tuesday, reaching $289.10. 2,033,650 shares of the stock were exchanged, compared to its average volume of 3,073,377. The firm has a market capitalization of $155.40 billion, a PE ratio of 37.04, a PEG ratio of 2.87 and a beta of 0.56. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company's 50-day simple moving average is $270.95 and its two-hundred day simple moving average is $303.82. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.29%. The ex-dividend date is Friday, February 14th. This is a positive change from Amgen's previous quarterly dividend of $2.25. Amgen's dividend payout ratio is presently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.